Haisco Pharma has announced that its shareholder, YCDL, who holds more than 5% of the shares, plans to reduce its shareholding by no more than 990,150 shares, or 1% of the total share capital of the company, through centralized bidding within three months after fifteen trading days from the disclosure date of the announcement.
海创药业：股东盈创动力拟减持不超过1%
Hailan Pharmaceutical: Shareholder Yingchuang Power plans to decrease shareholding by no more than 1%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.